Radionuclide procedures carried out on pregnant women also involve radiation dose to the foetus. Only essential investigations should therefore be carried out during pregnancy, when the likely benefit far exceeds the risk incurred by the mother and foetus. During pregnancy, lymphoscintigraphy involving the pelvis is strictly contraindicated due to the accumulation in pelvic lymph nodes.
Before administering radiopharmaceuticals to a mother who is breast-feeding consideration should be given to the possibility of delaying the administration of radionuclide until the mother has ceased breastfeeding, and to what is the most appropriate choice of radiopharmaceuticals, bearing in mind the secretion of activity in breast milk. If the administration is considered necessary, breastfeeding should be interrupted for 24 hours and the expressed feeds discarded.
Close contact with infants should be restricted during the initial 24 hours following injection.
When an administration of radiopharmaceuticals to a woman of childbearing potential is intended, it is important to determine whether or not she is pregnant. Any woman who has missed a period should be assumed to be pregnant until proven otherwise. If in doubt about her potential pregnancy (if the woman has missed a period, if the period is very irregular, etc.), alternative techniques, not using ionising radiation (if there are any) should be offered to the patient.
No studies on fertility have been performed.
Technetium 99mTc nanocolloid has no or negligible influence on the ability to drive and use machines.
The following table presents how the frequencies are reflected in this section:
Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from the available data)
Frequently not known: Protein allergic (hypersensitive) reaction, and hypersensitivity reactions (including very rare life-threatening anaphylaxis).
Very rare: local reactions, rash, itching, vertigo, hypotension
Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects. As the effective dose is 3.12mSv when the maximal recommended activity of 500 MBq is administered these adverse reactions are expected to occur with a low probability.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
